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Optimizing conjugated meningitis vaccine with flagellin adjuvants 
Project Aims- 
Bacterial meningitis is a common infection with worldwide prevalence, caused by the 
gram-negative bacteria Niesseria meningitidis.  It is a commensal organism with an obligate 
human host that colonizes the upper respiratory tract.  However, in some circumstances, 
the central nervous system can become infected, causing shock, swelling and inflammation 
which can be fatal, especially in infants and young children.   There are six different 
subtypes of N. meningitides, groups A, B, C, W-135, X and Y which are the strains primarily 
responsible for causing disease.  While N. meningitides is prevalent throughout the world, 
each region has different endemic subtypes.   
There are several different meningitis vaccines which are currently licensed, which 
protect against some of the six subtypes.  The targets for most of these vaccines are 
subtype-specific polysaccharides on the outer bacterial membrane, usually conjugated to a 
protein component.  While the primary mechanism of protective immunity from these 
vaccines is eliciting a bactericidal antibody titer against the membrane polysaccharide,[4] 
conjugation with a peptide or protein allows for the creation of lasting adaptive immunity 
via a T cell dependent mechanism.  Polysaccharides alone cannot be displayed on an MHC 
molecule which is the necessary first step in a memory response.  Despite the wide success 
of many vaccination campaigns, meningitis epidemics continue to occur to this day, 
primarily in what is known as the meningitis belt of sub-Saharan Africa[2].   However, no 
multivalent vaccine exists that can protect against all meningitis subtypes, and in particular 
subtype B is endemic in several regions and has been especially difficult to vaccinate 
against.  Additionally, there needs to be increased efficacy and cost-effectiveness for 
subtypes which are endemic in sub-Saharan Africa in order to create high enough 
immunity in the population to successfully decrease incidence of disease. 
Towards this end, we propose attempting to conjugate the meningococcal 
polysaccharide with flagellin as a carrier protein in order to produce a more effective 
vaccine[3].  This would serve the dual purpose of conjugating the polysaccharide to a 
protein component and thus exposing it to the adaptive immune system and enhancing 
antibody immunity, as well as serving as an intrinsic adjuvant.  Current meningitis vaccines 
are conjugated to a protein such as tetanus or diphtheria toxoid, which are sufficient to 
stimulate the immune system and produce immunologic memory.  However, flagellin is an 
agonist of the innate immune system, specifically toll like receptor (TLR) 5, and we believe 
that conjugation with this protein could prove to increase overall immunogenicity of the 
meningococcal polysaccharide. 
Specific Aim 1: Develop a system to conjugate meningococcal polysaccharides to 
flagellin adjuvant across different subtypes.  In order to test the hypothesis that 
conjugation with flagellin could be a beneficial adjuvant for next-generation meningitis 
vaccines, the first step is to develop a system of conjugation.   Conjugation involves a set of 
chemical reactions to activate the purified polysaccharide and protein for covalent bonding, 
and the initial aim will be to see whether this conjugation is possible, and develop a system 
of production.   In order to test efficacy of this system across all subtypes, distinct 
polysaccharides from each subtype would ideally be cross-linked to the flagellin, using 
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polysaccharides which have previously been identified as antibody targets in other 
vaccines, meaning that at least six flagellin-polysaccharide conjugates must be created, one 
from each main meningococcal subtype. 
Specific Aim 2: Test activation of toll-like receptors in vitro.   Once conjugate vaccine 
targets have been created, the next step is to test the immunogenicity of these constructs 
by seeing whether or not they activate toll-like receptors in vitro.  One of the main features 
of the pathogenesis of meningococcal disease is caused by inflammation mainly associated 
with the activation of TLR4 because of its high density of lipopolysaccharides on the 
bacterial cell wall.  However, by conjugating the vaccine with flagellin this should activate 
TLR5, which is another innate immune mechanism designed to protect against bacteria.  
Using a bacterial antigen to produce immunity against a bacterial pathogen would likely be 
a productive way to elicit a robust immune response against challenge without causing 
over-stimulation of the TLR4 pathway which can amplify disease progression.   By using an 
in vitro system with an immune competent cell line, activity of TLR pathways 4 and 5 can 
be assessed after introduction of this conjugate protein.  Ideally, TLR5 pathways would be 
activated, indicating that the flagellin is acting in its capacity as an adjuvant. 
Specific Aim 3: Assess immunogenicity and production of specific antibody titers 
using an animal model.  Although N. meningitidis is an obligate human pathogen, there do 
exist several animal models which can be used to assess immunogenicity of specific vaccine 
constructs.  In particular, using an inbred mouse line that has a well categorized immune 
system can be used to study the effects of the vaccine.  With this tool, we propose testing 
the production of antibodies against the meningococcal polysaccharide, and particularly 
whether or not these antibodies are in fact bactericidal and therefore capable of limiting 
infection.  A vaccination schedule will be developed involving an initial vaccination and 
then a booster shot some weeks later, and then assessing serum antibody levels after 
several more weeks.  If tests show what are thought to be protective antibody levels, there 
is the possibility of doing a challenge experiment post immunization.  Specifically, it would 
be prudent to not only test whether or not the flagellin-conjugated vaccine produces 
antibodies in general, but ideally we would compare this antibody titer to that of an already 
approved conjugate vaccine to see whether it produces a more robust immune response.   
One particular advantage that could be seen from conjugating the meningococcal 
polysaccharide with flagellin could be a decreased dose needed to produce immunity, 
which would help in overall cost-effectiveness.  Therefore, in the animal model, dose-
escalation studies would also be performed to compare antibody titers across different 
vaccine dosages. 
If these experiments prove to be successful, flagellin-conjugated vaccines for N. 
meningitidis could be a possible avenue for the development of future meningitis 
vaccines.  If a multivalent vaccine could be produced that is able to protect against all six 
subtypes with long lasting immunity, this could eventually be used to control and even 
eliminate bacterial meningitis from what are currently epidemic regions, and provide relief 
to a major global health burden. 
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Significance- 
Bacterial meningitis caused by N. meningitidis is a public health problem across the 
globe, in both developed and developing countries alike.  Meningitis is uniquely able to 
cause outbreaks even in communities with moderate vaccination rates[4], and so in order 
to achieve control of this disease, widespread and cost effective vaccinations must 
become available for all subtypes.   
Figure 1[4] shows the distribution of the various subtypes of meningitis globally, with 
emphasis placed on the so-called meningitis belt in sub-Saharan Africa where epidemics 
remain unfortunately common.  Also highlighted are regions where subtype B is prevalent, 
as this is the last major subtype to which a vaccine proves elusive. 
Historically, there have been multiple vaccines developed and licensed for 
prevention of meningitis.  The first was a simple purified polysaccharide, which induced 
antibody titers but because it did not contain a protein component was unable to create 
significant memory immunity and only lasted for several years[1].  Moreover, re-vaccination 
with this vaccine was unsafe, as it could cause antibody-dependent adverse effects and 
actually increase disease upon meningococcal infection.  Later, conjugated vaccines were 
developed, using tetanus and diphtheria toxoid as a peptide base.  Now, there are two fully 
licensed conjugate vaccines, targeting subtypes A, C, W135, and Y, and two more recently 
developed quadrivalent vaccines undergoing licensure processes in the European Union[1].  
One bivalent vaccine has been developed targeting specifically subtypes C and Y.  The only 
conjugate vaccine specifically targeting subtype A meningitis was recently licensed through 
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grant money established through The Meningitis Project, which is a foundation dedicated 
to stopping meningitis outbreaks mostly in sub-Saharan Africa[2].  While several vaccine 
candidates have been made to subgroup B, which is especially prevalent and causes 
ongoing outbreaks in Australia, New Zealand, and the Pacific, there are currently safety and 
licensure concerns due to antigenic similarity between meningococcal polysaccharides and 
human neuronal tissue.  
It is clear from the number and variety of vaccines available that there is not yet a 
single optimal vaccine to prevent bacterial meningitis.  It has been documented that 
differences in vaccination recommendations can cause pockets of unvaccinated and 
therefore vulnerable populations.  These differences include which populations and age 
ranges can be vaccinated effectively using different vaccines, the longevity of protection 
which is elicited, and the subtype vaccinated against, all of which vary by country.  An 
additional consideration when producing a meningitis vaccine is cost.  It was one of the 
goals of The Meningitis Project, when developing a subtype A conjugate vaccine for sub-
Saharan Africa, that each dose cost less than $0.50.  While this goal was achieved, and 
subtype A vaccination is now feasible in many countries in the meningitis belt, this still 
leaves populations susceptible to other subtypes, as quadrivalent vaccines are more costly.  
There is also the possibility of emerging new virulent strains, such as was seen with the 
appearance of the W-135 strain in Africa in the last decade.  This makes it especially 
important to optimize vaccines to the strains we already know about, and hopefully 
develop improved delivery systems that can be used in the event of an appearance of a new 
strain. 
All in all, vaccine coverage against meningitis needs to be improved in order to 
prevent future epidemics.  By conjugating the vaccine with not a simple peptide delivery 
system, but a flagellin which can serve the secondary function as an adjuvant, it stands to 
reason that there could be improved immunogenicity, which could correlate to better 
protection against meningitis.  
Research Design and Methods- 
The main focus of this research would be to develop an efficient conjugation system for 
flagellin and meningococcal polysaccharides.  In order to do this, the well-characterized 
polysaccharides from among the different meningitis subtypes would be used, eliminating 
the need to find and categorize our own polysaccharides.  Similarly, as flagellin-conjugated 
antigens have been researched as adjuvants in other contexts, it would be possible to use 
established bacterial strains to produce the flagellin and purify it for conjugation.  There 
are many different chemical reagents and reactions that can be used for covalently 
attaching different chemical structures,  and this work would be a matter of deciding on a 
set of optimal protocols given the structure of the polysaccharides and flagellin that can 
then be tested to see which works the best.  The immunogenicity studies can likewise be 
carried out using established cell lines and mouse lines and standard assays for TLR 
activity, as well as detection and characterization of serum antibodies. 
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Future Directions- 
If a flagellin-conjugated vaccine proves to be viable to produce and a suitably immunogenic 
construct, the next steps in furthering this research would be to conduct safety and efficacy 
studies.  If the ultimate goal is to produce a vaccine that would be able to protect against all 
six subtypes, the different conjugates would need to be studied in combination to ascertain 
the optimal ratio of subtypes to provide protective immunity.  Any additional safety 
concerns that have arisen during the initial testing would need to be addressed.  Efficacy 
would need to be further tested as well, ensuring that immunologic memory has been 
established, and there is long-term persistence of antibodies.  Dose escalation studies in an 
animal model would also be an essential feature.  If, at the end of these studies, the 
flagellin-conjugated vaccine seems to stand up to measure with established vaccine 
standards for other meningitis vaccines, it could conceivably be advanced to human clinical 
trials. 
Timeline- 
Year 1- 2: The first year or two would certainly be spent constructing as many subtype 
conjugates as possible, with the goal of establishing polysaccharides for all six subtypes 
with a flagellin.  Much of this time would likely be spent optimizing protocols and 
preparing quantities or a production scheme large enough to use in later immunogenicity 
studies. 
Year 2-3:  Immunogenicity of the constructs will be assessed during this time, both in vitro 
and in vivo.  First the viability of the constructs should be verified, followed by an 
assessment of immune activity. 
Budget- 
Reagents and materials for cloning…………………………………$5,000 
Tissue culture supplies…………………………………………………$10,000 
Immunogenicity assays…………………………………………………..$5,000 
Mouse line purchase and upkeep………..…………………………$15,000 
Equipment and maintenance…………………………………………..$5,000 
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